Characteristics and Disease Severity of US Children and Adolescents Diagnosed With COVID-19 | Adolescent Medicine | JAMA Network Open | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 35.170.64.36. Please contact the publisher to request reinstatement.
1.
American Academy of Pediatrics and the Children’s Hospital Association. Children and COVID-19: state data report: a joint report from the American Academy of Pediatrics and the Children’s Hospital Association. Version 12/24/20. Accessed December 31, 2020. https://downloads.aap.org/AAP/PDF/AAP%20and%20CHA%20-%20Children%20and%20COVID-19%20State%20Data%20Report%2012.24.20%20FINAL.pdf
2.
Kim  L, Whitaker  M, O’Halloran  A,  et al; COVID-NET Surveillance Team.  Hospitalization rates and characteristics of children aged <18 years hospitalized with laboratory-confirmed COVID-19—COVID-NET, 14 states, March 1-July 25, 2020.   MMWR Morb Mortal Wkly Rep. 2020;69(32):1081-1088. doi:10.15585/mmwr.mm6932e3 PubMedGoogle ScholarCrossref
3.
Premier Applied Science. Premier healthcare database (COVID-19): data that informs and performs. April 2020. Accessed December 30, 2020. http://offers.premierinc.com/rs/381-NBB-525/images/PHD_COVID-19_White_Paper.pdf
4.
Agency for Healthcare Research and Quality: Healthcare Cost and Utilization Project, Chronic Condition Indicators for ICD-10-CM. Accessed August 26, 2020. https://www.hcup-us.ahrq.gov/toolssoftware/chronic_icd10/chronic_icd10.jsp
5.
Stokes  EK, Zambrano  LD, Anderson  KN,  et al.  Coronavirus disease 2019 case surveillance—United States, January 22-May 30, 2020.   MMWR Morb Mortal Wkly Rep. 2020;69(24):759-765. doi:10.15585/mmwr.mm6924e2 PubMedGoogle ScholarCrossref
6.
Martin  S, Wagner  J, Lupulescu-Mann  N,  et al.  Comparison of EHR-based diagnosis documentation locations to a gold standard for risk stratification in patients with multiple chronic conditions.   Appl Clin Inform. 2017;8(3):794-809. doi:10.4338/ACI-2016-12-RA-0210 PubMedGoogle ScholarCrossref
Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    3 Comments for this article
    What About Mortality?
    Eduardo Quinteros, MD | Clinica Mayo Bell Ville
    The authors mention death, but how many deaths were there?
    CONFLICT OF INTEREST: None Reported
    Same Question about Deaths
    Stanley Schwartz, MD | WellOK, The Northeastern Oklahoma Business Coalition on Health
    As in the previous comment, the authors included death in the category of severe COVID-19 infection. Not reporting actual mortality seems intentional. Why?
    CONFLICT OF INTEREST: None Reported
    Patient Sample
    Bradette Varilek, MD |
    Given that the sample was taken from inpatients and ER visits I wonder if it is biased towards a sicker group. What about drive-in clinics and outpatient visits? The national data shows 1-2% hospitalized, not 12%. This seems a little high to me.
    CONFLICT OF INTEREST: None Reported
    Views 22,393
    Citations 0
    Research Letter
    Infectious Diseases
    April 9, 2021

    Characteristics and Disease Severity of US Children and Adolescents Diagnosed With COVID-19

    Author Affiliations
    • 1COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia
    • 2Epidemic Intelligence Service, Center for Surveillance, Epidemiology, and Laboratory Services, Centers for Disease Control and Prevention, Atlanta, Georgia
    • 3Commissioned Corps, US Public Health Service, Rockville, Maryland
    JAMA Netw Open. 2021;4(4):e215298. doi:10.1001/jamanetworkopen.2021.5298

    In 2020, more than 2 000 000 pediatric COVID-19 cases were reported in the United States.1 Although approximately half of pediatric patients with COVID-19 experience mild disease, some children require admission to intensive care units or use of invasive mechanical ventilation.2 We conducted a cohort study to estimate adjusted associations between demographic and clinical characteristics and severe COVID-19 among hospitalized pediatric patients.

    Discharge data from 869 medical facilities that contributed inpatient and emergency department encounters to the Premier Healthcare Database Special COVID-19 Release (PHD-SR) (release date, December 9, 2020), an administrative all-payer database capturing approximately 20% of US hospitalizations,3 were used to describe patients 18 years or younger who had an inpatient or emergency department encounter with a primary or secondary COVID-19 discharge diagnosis from March 1 through October 31, 2020. The International Statistical Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) diagnosis code U07.1 was used from April 1 through October 31, 2020, and code B97.29 was used from March 1 through April 30, 2020. The discharge data were also used to estimate associations between demographic and clinical characteristics and severe COVID-19 among pediatric patients hospitalized with COVID-19. This study was reviewed by the Centers for Disease Control and Prevention and was deemed exempt from institutional review board oversight per 45 CFR §46.101(b)(4) and exempt from patient informed consent based on 45 CFR §164.506(d)(2)(ii)(B) because the disclosed PHD-SR data are considered deidentified. This study followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline.

    ×